Cardiff Oncology Inc (NASDAQ:CRDF)’s traded shares stood at 1.06 million during the last session, with the company’s beta value hitting 1.88. At the close of trading, the stock’s price was $4.34, to imply an increase of 10.71% or $0.42 in intraday trading. The CRDF share’s 52-week high remains $6.42, putting it -47.93% down since that peak but still an impressive 67.51% since price per share fell to its 52-week low of $1.41. The company has a valuation of $288.69M, with an average of 3.3 million shares in intraday trading volume over the past 10 days and average of 1.92 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cardiff Oncology Inc (CRDF), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CRDF a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.25.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
After registering a 10.71% upside in the last session, Cardiff Oncology Inc (CRDF) has traded red over the past five days. The 5-day price performance for the stock is -3.34%, and 77.14% over 30 days. With these gigs, the year-to-date price performance is 193.24%. Short interest in Cardiff Oncology Inc (NASDAQ:CRDF) saw shorts transact 8.18 million shares and set a 8.06 days time to cover.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Looking at statistics comparing Cardiff Oncology Inc share performance against respective industry, we note that the company has underperformed competitors. Cardiff Oncology Inc (CRDF) shares are 86.27% up over the last 6 months, with its year-to-date growth rate lower than industry average at -6.45% against 16.70%. The rating firms project that company’s revenue will grow 21.48% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 73k. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 76k.Earnings reports from the last fiscal year show that sales brought in 156k and 205k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -53.21% before dropping -62.93% in the following quarter.
CRDF Dividends
Cardiff Oncology Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Cardiff Oncology Inc insiders hold 5.62% of total outstanding shares, with institutional holders owning 27.66% of the shares at 29.30% float percentage. In total, 27.66% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 2.63 million shares (or 5.883% of shares), all amounting to roughly $5.84 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 2.14 million shares, or about 4.7816% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.74 million.
